Pregabalin versus Gabapentin in the Management of Painful Diabetic Neuropathy

Dr. Tejvir Singh1, Dr. Sumit Pal Singh Chawla2, Dr. Monika Gulia3, Dr. Sarabjot Kaur4

1Assistant Professor, Deptt. Of Medicine, Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram, Wardha, Maharashtra, India- 442102
2Assistant Professor, Deptt. Of Medicine, Guru Gobind Singh Medical College & Hospital (GGS MC&H), Faridkot, Punjab, India -151203
3PG Resident, Deptt. Of Paediatrics, Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram, Wardha, Maharashtra, India- 442102
4Senior Resident, Deptt. Of Medicine, Guru Gobind Singh Medical College & Hospital (GGS MC&H), Faridkot, Punjab, India -151203

*Corresponding author
Dr. Sumit Pal Singh Chawla
Email: drsumitpsc@gmail.com

Abstract: Diabetic neuropathy develops in the majority of poorly controlled diabetic patients as a late complication. Painful diabetic neuropathy represents a major health problem as it may present with excruciating neuropathic pain and is responsible for substantial morbidity, increased mortality and impaired quality of life. The aim is to compare the efficacy of Pregabalin and Gabapentin in painful diabetic neuropathy. This study was conducted on 100 diagnosed patients of diabetes with painful diabetic neuropathy presenting in the department of Medicine of a tertiary care teaching hospital of Punjab, India. Patients were divided in two groups of 50 each. Pregabalin (150-300 mg/day) was administered to group I and Gabapentin (300-2400 mg/day) to group II for 6 weeks. Follow up assessment of various clinical parameters was done at weekly intervals while Visual Analogue Scale (VAS) Score and Likert Scale Score assessments were done at 2, 4 and 6 weeks of treatment. Overall, it was observed that both Pregabalin and Gabapentin showed an improvement in VAS score and Likert scale score, but the improvement was significantly more with Pregabalin than Gabapentin. In this study, Pregabalin was clearly superior to Gabapentin in the improvement of parameters like spontaneous pain, burning sensation and numbness. This study concluded that it is important to treat patients with painful diabetic neuropathy with tailor-made approach. Monotherapy with Pregabalin or Gabapentin produced clinically meaningful pain relief however; pain reduction was superior with Pregabalin compared to Gabapentin. Therefore, it is suggested that Pregabalin could be a better therapeutic option in patients with painful diabetic neuropathy.

Keywords: diabetes, painful, neuropathy, Pregabalin, Gabapentin

Key Messages: Early identification and treatment of painful diabetic neuropathy is of utmost importance to prevent significant morbidity associated with it. Besides good glycemic control, both Pregabalin and Gabapentin produce clinically meaningful pain relief; however pain reduction is superior with Pregabalin as compared to Gabapentin. In the face of recent advances in treatment modalities, the future prospective management of diabetic neuropathy appears bright and convincing.

INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia together with disturbances of carbohydrate, fat and protein metabolism resulting from defects of insulin secretion, insulin action or both. DM is associated with wide spectrum of neuropathic syndromes. The diabetic neuropathies are heterogeneous in nature, ranging from a mild asymptomatic distal sensory neuropathy to a severe disabling radiculoplexus neuropathy.

Diabetic neuropathy is the most common complication of long standing DM and through its much feared sequel, the diabetic foot, is responsible for most diabetes related hospitalization [1]. It is estimated that at least 20% of adults with diabetes have at least one manifestation of diabetic neuropathy. Most common among the neuropathies are chronic sensorimotor distal symmetric polyneuropathy and autonomic neuropathies. Diabetic peripheral neuropathic pain (DPNP) affects approximately 11% of patients with diabetic peripheral neuropathy.
neuropathy (DPN). Neuropathic pain may be stimulus evoked (e.g., allodynia) or stimulus-independent (spontaneous) pain that may be continuous or intermittent. Spontaneous pain often is paroxysmal and described by patients as shooting, stabbing or electric in nature [2]. Neuropathic pain has been associated with impaired quality of life, reduced individual productivity and increased patient and healthcare resource expenditure [3, 4]. Co-morbid conditions include sleep disturbances, depression and anxiety disorders [4], increasing even further the economic burden to the healthcare system.

Several mechanisms may be responsible for the development of DPN [5, 6]. They include microangiopathy with endoneural hypoxia, excessive oxidative stress with overproduction of harmful reactive oxygen species, defect in macrophage function and inflammatory repair, reduced regenerative activity of Schwann cells and impaired neuronal cell body response caused by deficient neurotrophic support [6].

Therapeutic options for diabetic neuropathy [7] include treatment of hyperglycemia, tricyclic and other anti-depressants (e.g. Amitriptyline, Nortriptyline, Desipramine, Venlafaxine, Duloxetine), anti-convulsants (e.g. Pregabalin, Gabapentin, Carbamazepine, Phenytoin, Lamotrigine, Topiramate), anti-arrhythmics (e.g. Mexiletine), Aldose Reductase inhibitors (e.g. Epalrestat, Ranirestat, Fidarestat, Zenarestat, Tolrestat, Zopolrestat), α-lipoic acid, Methylcobalamin, Nerve Growth Factors (Neurotrophins), Protein kinase C β inhibitor (Roboxistaurin), topical agents (Capsaicin) and Transcutaneous Electrical Nerve Stimulation (TENS).

Both Pregabalin and Gabapentin share similar mechanism of action such as binding to calcium channel and modulating calcium influx as well as influencing GABAnergic neurotransmission [8]. The recommended starting dosage of Pregabalin is 150 mg/day, taken in two or three divided doses. Based on individual patient response and tolerability, the dose may be gradually increased, to a maximum of 600 mg/day. Clinical trials using Pregabalin for both peripheral and central neuropathic pain, showed a reduction in pain scores within the first week, which was maintained throughout the treatment period [9, 10]. Alternatively, the starting dose of gabapentin is 900 mg/day given as three equally divided doses, increasing gradually up to a maximum daily dose of 3,600 mg.

Painful diabetic neuropathy represents a major health problem and its management remains a challenge for the physicians. The present study was planned to compare the efficacy of two commonly used drugs, Pregabalin and Gabapentin, in the management of painful diabetic neuropathy so as to facilitate decision-making in providing the best therapeutic option for this condition.

MATERIAL AND METHODS
This study was conducted in the department of Medicine of a tertiary care teaching hospital of Punjab, India. It was a prospective randomized single blind parallel group single center observational study of 100 diagnosed patients of diabetes with painful diabetic neuropathy admitted in the medical wards or attending the out-patient department. The study was conducted after obtaining the permission of the institutional ethics committee. Written informed consent was taken from each subject before enrolling him/her for the study. The data was collected by the first author as per the detailed questionnaire. Following detailed history and thorough clinical examination, necessary investigations were undertaken in all the patients like hemoglobin, total leucocyte count (TLC), differential leucocyte count (DLC), fasting blood sugar, post prandial blood sugar, renal function tests, liver function tests, Chest X-ray and electrocardiograph (ECG).

Following two groups were compared in this study:

- Group I: Comprised of 50 cases, which were given Pregabalin, starting with 75 mg twice daily. Dose was titrated up to a maximum of 300 mg/day according to improvement of pain, side effects and patient compliance.
- Group II: Comprised of 50 cases, which were given Gabapentin, starting with 300 mg once daily. Dose was titrated up to a maximum of 2400 mg/day according to improvement of pain, side effects and patient compliance.

Patients were followed at weekly intervals for 6 weeks. Patients not improving with Pregabalin or Gabapentin were excluded from the study.

Inclusion Criteria
1. Diagnosed patients of DM (controlled or uncontrolled) with clinical signs and symptoms suggestive of painful diabetic neuropathy.

Exclusion Criteria
1. Patients with DM having any other disease known to cause peripheral neuropathy like chronic kidney disease, liver failure, post herpetic neuralgia, etc.
2. Patients with DM on drugs known to cause peripheral neuropathy like Isoniazid, Phenytoin, Amiodarone, Nitrofurantoine, etc.
3. Patients with DM with history of chronic alcoholism.
4. Patients of peripheral diabetic neuropathy having pain intensity of VAS score < 40 mm or Likert scale score < 4.
5. Patients with altered sensorium or disturbed cognitive status.
Assessment of Diabetic Neuropathy:

Both subjective and objective assessments were undertaken.

(A) Subjective: For painful diabetic neuropathy assessment, the following pain scales were used:
1. Visual Analogue Scale (VAS): VAS is a scale 100 mm long with 1 mm markings, marked from 0 to 100. Patients mark the point on the scale that they feel represents their pain perception.
2. Likert Scale: It is an 11 point symptoms severity scale; 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-9: severe symptoms, 10: worst imaginable symptoms.

Only patients with > 40 mm pain intensity measurement on VAS scale and > 4 point score on Likert scale were included in this study.

(B) Objective: Quantitative Sensory Testing (QST) was used as objective method for assessment of diabetic neuropathy. Sensations were measured on a three-point scale (0-absent, 1-reduced, and 2-normal) for the following parameters in the hands and the feet: vibration perception examined with a 128 Hz tuning fork, pain sensation with a disposable pin, light touch with Semmes Weinstein monofilament, joint position on the fingers and the toes, and thermal sensation with thermo test tubes containing hot and cold water.

RESULTS

In this study of 100 patients with 50 patients in each Pregabalin and Gabapentin group, both male to female ratio (1 and 0.9 respectively) and the mean age of patients in the two groups were comparable (56.84 ± 6.48 years and 57.24 ± 6.34 years respectively).

All the 50 cases in both the groups had burning sensation at baseline. At the end of treatment, i.e. 6 weeks, there was significantly more improvement in the Pregabalin group with 24 patients recovered from burning sensation (48%) compared to the Gabapentin group, where only 18 patients recovered from burning sensation (36%) (Table 1).

Table 1: Effect on burning sensation

<table>
<thead>
<tr>
<th>Duration in weeks</th>
<th>Study population with burning sensation</th>
<th>Pregabalin(n=50)</th>
<th>Gabapentin(n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of cases</td>
<td>%</td>
<td>No. of cases</td>
</tr>
<tr>
<td>Baseline</td>
<td>50</td>
<td>100.0</td>
<td>50</td>
</tr>
<tr>
<td>1 week</td>
<td>48</td>
<td>96.0</td>
<td>50</td>
</tr>
<tr>
<td>2 weeks</td>
<td>45</td>
<td>90.0</td>
<td>49</td>
</tr>
<tr>
<td>3 weeks</td>
<td>42</td>
<td>84.0</td>
<td>46</td>
</tr>
<tr>
<td>4 weeks</td>
<td>38</td>
<td>76.0</td>
<td>42</td>
</tr>
<tr>
<td>5 weeks</td>
<td>33</td>
<td>66.0</td>
<td>37</td>
</tr>
<tr>
<td>6 weeks</td>
<td>26</td>
<td>52.0</td>
<td>32</td>
</tr>
</tbody>
</table>

In each group, 38 patients (76%) had spontaneous pain at baseline. However, after 6 weeks treatment, the Pregabalin group showed a significant improvement in symptoms in 12 patients (31.57%) as compared to the Gabapentin group in which only 7 patients got relief (18.42%) at the end of 6th week (Table 2).

Table 2: Effect on spontaneous pain

<table>
<thead>
<tr>
<th>Duration in weeks</th>
<th>Study population with spontaneous pain</th>
<th>Pregabalin(n=50)</th>
<th>Gabapentin(n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of cases</td>
<td>%</td>
<td>No. of cases</td>
</tr>
<tr>
<td>Baseline</td>
<td>38</td>
<td>76.0</td>
<td>38</td>
</tr>
<tr>
<td>1 week</td>
<td>37</td>
<td>74.0</td>
<td>38</td>
</tr>
<tr>
<td>2 weeks</td>
<td>36</td>
<td>72.0</td>
<td>37</td>
</tr>
<tr>
<td>3 weeks</td>
<td>33</td>
<td>66.0</td>
<td>36</td>
</tr>
<tr>
<td>4 weeks</td>
<td>31</td>
<td>62.0</td>
<td>34</td>
</tr>
<tr>
<td>5 weeks</td>
<td>28</td>
<td>56.0</td>
<td>33</td>
</tr>
<tr>
<td>6 weeks</td>
<td>26</td>
<td>52.0</td>
<td>31</td>
</tr>
</tbody>
</table>

In this study, 43 out of 50 patients in Pregabalin group (86%) and 42 out of 50 patients in Gabapentin group (84%) had numbness at baseline. After 6 weeks, the proportion of cases with numbness had significantly fallen from baseline in both the groups and the efficacy in Pregabalin group was better where 23 patients recovered (53.5%) in comparison to Gabapentin group where only 14 patients (33.5%) got relief from numbness. All the 100 cases from both the groups showed absent to reduced sensation at baseline. After 6 weeks treatment, significantly more number of cases i.e. 11 patients (22%) from the Pregabalin group had normal sensation as compared to the Gabapentin group.
in which 6 patients (12%) regained normal sensation (Table 3).

<table>
<thead>
<tr>
<th>Duration in weeks</th>
<th>Sensation in study population</th>
<th>Gabapentin</th>
<th>Pregabalin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Absent</td>
<td>Reduced</td>
<td>Normal</td>
</tr>
<tr>
<td>Baseline</td>
<td>24(48.0%)</td>
<td>26(52.0%)</td>
<td>-</td>
</tr>
<tr>
<td>1 week</td>
<td>23(46.0%)</td>
<td>27(54.0%)</td>
<td>-</td>
</tr>
<tr>
<td>2 weeks</td>
<td>21(42.0%)</td>
<td>27(54.0%)</td>
<td>2(04.0%)</td>
</tr>
<tr>
<td>3 weeks</td>
<td>18(36.0%)</td>
<td>28(56.0%)</td>
<td>4(08.0%)</td>
</tr>
<tr>
<td>4 weeks</td>
<td>15(30.0%)</td>
<td>30(60.0%)</td>
<td>5(10.0%)</td>
</tr>
<tr>
<td>5 weeks</td>
<td>11(22.0%)</td>
<td>31(62.0%)</td>
<td>8(16.0%)</td>
</tr>
<tr>
<td>6 weeks</td>
<td>7(14.0%)</td>
<td>32(64.0%)</td>
<td>11(22.0%)</td>
</tr>
</tbody>
</table>

In this study, both the groups were comparable in terms of severity of pain at baseline and there was no statistically significant difference (p>0.05) in the mean value of VAS score at baseline, which was 86.44 ± 2.79 mm and 86.64 ± 2.80 mm respectively in the right and left foot in the Pregabalin group and 86.60 ± 3.56 mm and 86.62 ± 3.57 mm respectively in the right and left foot in the Gabapentin group. However, it was seen that at the end of 6 weeks, there was statistically significant difference (p<0.05) in its mean value in the two study groups; the VAS score at the end of 6 weeks in the right and left foot was 38.90 ± 5.70 mm and 38.96 ± 5.54 mm respectively in the Pregabalin group and 41.62 ± 4.79 mm and 41.62 ± 4.89 mm respectively for the Gabapentin group. The mean improvement in VAS Score after 6 weeks of treatment with Pregabalin was 47.54 ± 4.94 mm in right foot & 47.68 ± 4.97 mm in left foot; and the mean improvement in VAS Score after 6 weeks of treatment with Gabapentin was 44.98 ± 4.46 mm in right foot & 45.00 ± 4.54 mm in left foot. So, the improvement in VAS Score was significantly (p<0.01) more in Pregabalin group as compared to Gabapentin group (Table 4).

Mean value of Likert scale scores also showed no statistically significant difference (p>0.05) at baseline in the two study groups, which was 7.70 ± 0.83 and 7.78 ± 0.86 respectively in the right and left foot in the Pregabalin group and 7.86 ± 0.78 and 7.86 ± 0.89 respectively in the right and left foot in the Gabapentin group. However, at the end of 6 weeks, there was statistically significant difference (p<0.01) in the mean value of Likert scale scores in the two study groups, with 2.78 ± 0.58 and 2.68 ± 0.55 in the right and left foot respectively in the Pregabalin group and 4.44 ± 0.61 and 4.34 ± 0.65 in the right and left foot respectively in the Gabapentin group. The mean improvement in Likert scale score after 6 weeks of treatment with Pregabalin was 4.92 ± 0.94 in right foot & 5.10 ± 0.86 in left foot; and the mean improvement in Likert scale score after 6 weeks of treatment with Gabapentin was 3.42 ± 0.64 in right foot & 3.34 ± 0.65 in left foot. So, in this study, at the end of 6 weeks, the improvement in Likert Scale Score was significantly (p<0.01) more in Pregabalin group as compared to Gabapentin group (Table 5).

**DISCUSSION**

Neuropathic pain carries a great disease burden for patients and, is also associated with a significant economic burden. There are a limited number of direct head-to-head comparison studies reported for drugs used in the treatment of painful diabetic neuropathy. In the present study, the efficacy of Pregabalin and Gabapentin was compared in patients with painful diabetic neuropathy. Both the drugs were administered for 6 weeks and their effects on pain and other parameters like burning sensation and numbness were...
Effect on burning sensation:
At the end of 6 weeks treatment, more patients in the Pregabalin group (48%) recovered from burning sensation as compared to the Gabapentin group (36%).

Effect on spontaneous pain:
Pregabalin was found to be superior to Gabapentin in providing relief from spontaneous pain as more patients in the Pregabalin group showed improvement in their symptoms (31.57%) at the end of 6 weeks as compared to those in the Gabapentin group (18.42%).

Effect on numbness:
Pregabalin was also found to be more effective than Gabapentin in reducing numbness. At the end of 6 weeks, 53.5% patients in the Pregabalin group recovered from numbness as compared to Gabapentin group where only 33.3% patients got relief from numbness.

Effect on sensations:
Objective assessment of sensations also revealed superiority of Pregabalin over Gabapentin. After 6 weeks therapy, significantly more (22%) number of cases from the Pregabalin group had normal sensation as compared to those in the Gabapentin group (12%).

Effect on VAS and Likert Scale Scores:
VAS score was measured for all the patients in both the groups at baseline and there was no statistically significant difference (p>0.05) in the mean value of VAS Score at baseline in the two study groups. At the end of 6 weeks, both the groups demonstrated a decrease in the VAS scores, however, there was statistically significant difference (p<0.05) in the mean value of VAS Score in the two study groups. The improvement in VAS Score was significantly (p<0.01) more in the Pregabalin group as compared to the Gabapentin group. Similar trend was noted with the Likert scale scores. At the end of 6 weeks, the improvement in Likert scale score was significantly (p<0.01) more in the Pregabalin group as compared to the Gabapentin group.

Thus, both drugs showed an improvement in VAS score and Likert scale score which suggests that both drugs are effective in painful diabetic neuropathy. But, in comparison to Gabapentin, Pregabalin resulted in more improvement in the VAS score and Likert scale score. This is further supported by the improvement in subjective symptoms (spontaneous pain, numbness and burning sensation).

Richter et al.; [11] in their study observed that Pregabalin 300mg/day provided greater than 50% reduction in mean pain score from baseline in 40% of patients. Rosenstock J et al.; [12] also reported improvement in mean neuropathic score in 67% of Pregabalin treated patients. Similar results were observed by Lesser et al.; [13].

In seven double-blind, randomized, placebo-controlled trials using Pregabalin to treat painful DPN with dosages of 150, 300, and 600 mg/d, administered over a duration of 5-13 weeks, it has been shown that Pregabalin significantly reduced pain and pain-related sleep interference associated with DPN [14].

Backjona et al.; [15] in their study of 165 diabetic patients reported a significant decrease in the mean pain score from 6.4 on Likert scale at baseline to 3.9 after 12 weeks of therapy with Gabapentin compared to placebo (from 6.5 to 5.1). Gabapentin-treated subjects also demonstrated statistically significant (p<0.05) benefits as depicted using sleep interference scores, total pain quality scores, quality of life scores and mood assessments.

Toth et al.; [16] in their study substituted Gabapentin with Pregabalin in patients with diabetic peripheral neuropathy. Results showed that both previous responders and non-responders to gabapentin had additional pain relief of approximately 25% after initiation of Pregabalin. Another study by Tarride et al.; showed that 12 weeks therapy with Pregabalin was associated with nine additional days with no or mild pain, against six additional days with Gabapentin therapy [16].

Athanasakis et al.; in their study compared Pregabalin with Gabapentin in the management of peripheral neuropathic pain associated with diabetic neuropathy. Mean pretreatment pain scores were identical (6.9) for both Pregabalin and Gabapentin. Post-treatment pain score mean values were 4.1 for Pregabalin and 4.8 for Gabapentin which was statistically significant. Pregabalin also demonstrated a statistically significant reduction in days with moderate to severe pain when compared to Gabapentin [17].

Rodriguez et al.; [3] in their study also supported the superiority of Pregabalin over Gabapentin in painful diabetic neuropathy. They reported that as compared to Gabapentin, Pregabalin yielded an estimated mean of 8 additional days with no or mild pain, 6 days with ≥30% reduction in pain intensity, 9 days with ≥50% reduction in pain intensity, and a gain of 0.1186 quality-adjusted life-years (QALYs).

Limitations in our study:
I) This was an open label design.
II) Sample size was small.
III) Follow-up of patients was only for 6 weeks and therefore, the long term efficacy and safety of the study drugs could not be assessed.

CONCLUSION:
Diabetic neuropathy develops in the majority of poorly controlled diabetic patients as a late
complication. Treatment is of utmost importance as it accounts for significant morbidity and economic burden. 60-70 percent of these patients may progress to even serious complications like diabetic foot and amputation. The treatment of diabetic neuropathy includes symptomatic relief of complications besides good glycemic control.

In the present study both Pregabalin and Gabapentin showed an improvement in VAS score and Likert scale score, but the improvement was significantly more with Pregabalin than Gabapentin. In this study, Pregabalin was clearly ahead of Gabapentin in efficacy parameters like improvement in spontaneous pain, burning sensation and numbness.

So, from the present study we conclude that monotherapy with Pregabalin or Gabapentin produces clinically meaningful pain relief in patients with painful diabetic neuropathy and pain reduction is superior with Pregabalin compared to Gabapentin. Therefore, it is suggested that these findings should be considered in the decision-making process when choosing the therapeutic option for the treatment of diabetic neuropathic pain. However, further studies in larger number of patients and for longer duration are necessary to confirm the benefits of Pregabalin over Gabapentin.

REFERENCES

Available online at http://saspublisher.com/sajb/